A phenotypic cell-based extracellular matrix deposition assay for target validation and drug discovery

M. Gerckens (München, Germany)

Source: International Congress 2017 – Lung fibrosis: basic science
Session: Lung fibrosis: basic science
Session type: Thematic Poster
Number: 912
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Gerckens (München, Germany). A phenotypic cell-based extracellular matrix deposition assay for target validation and drug discovery. 912

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A phenotypic high-throughput screening assay for the pharmacological inhibition of the pathological deposition of extracellular matrix
Source: ERS Lung Science Conference 2018
Year: 2018

Clinically validated markers of the extracellular matrix remodelling are altered by potential anti-fibrotic compounds in a human lung fibrosis ex vivo model
Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control
Year: 2018



RNAscope in situ hybridization allows spatial estimation of free drug exposure through quantification of drug induced gene expression
Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more
Year: 2019

In vivo pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-α converting enzyme and matrix metalloproteinases, in models of airway inflammation
Source: Eur Respir J 2002; 20: Suppl. 38, 169s
Year: 2002

Modern molecular direct tests for rapid identification and drug susceptibility testing of Mycobacterium tuberculosis
Source: Annual Congress 2012 - Microbiological advances in the diagnosis of tuberculosis
Year: 2012

Comparison of drug delivery from spacers using a standard in vitro and an ex vivo method
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008

Comparative mycobacterial genomics as a tool for drug target and antigen discovery
Source: Eur Respir J 2002; 20: 78S-86S
Year: 2002



Time-resolved proteomic characterization of ECM remodelling in human lung scaffold cultures using stable isotope labelling
Source: ERS Lung Science Conference 2018
Year: 2018

Patient derived lung tissue cultures for drug identification and validation
Source: International Congress 2017 – Innovative approaches to model human lung diseases
Year: 2017


Development of in vitro assays to predict fibrogenesis and replace animal testing
Source: Eur Respir J 2006; 28: Suppl. 50, 521s
Year: 2006

Proteomics of serum extracellular vesicles identifies a novel COPD biomarker, fibulin-3 from elastic fibres
Source: ERJ Open Res, 7 (1) 00658-2020; 10.1183/23120541.00658-2020
Year: 2021



T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation
Source: Eur Respir J, 51 (3) 1800153; 10.1183/13993003.00153-2018
Year: 2018



Gene expression profiling: identifying novel gene targets for therapeutic intervention
Source: Annual Congress 2008 - PG8 - Cellular and molecular technologies of today - treatments of tomorrow
Year: 2008



Genetic studies as a tool for identifying novel potential targets for treatment of COPD
Source: Eur Respir J, 50 (5) 1702042; 10.1183/13993003.02042-2017
Year: 2017



Genomics-based identification of targets in pathogenic bacteria for potential therapeutic use
Source: Annual Congress 2004 - Novel approaches to the treatment of pneumonia
Year: 2004

SFTA3, a novel protein of the lung: three-dimensional structure, characterisation and immune activation
Source: Eur Respir J 2014; 44: 447-456
Year: 2014